Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Illumina (ILMN) Stock Price & Analysis

4,723 Followers

ILMN Stock Chart & Stats

$209.55-$3.38(-1.59%)
At close: 4:00 PM EST
$200$225$250$275Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$197.81 - $211.75
52-Week Range
$112.65 - $309.35
Previous Close
$212.93
Volume
N/A
Average Volume (3M)
2.46M
Market Cap
$32.20B
Enterprise Value
$42.56B
Total Cash (Recent Filing)
$1.34B
Total Debt (Recent Filing)
$2.31B
Price to Earnings (P/E)
35.5
Beta
1.27
Next Earnings
Feb 11, 2027 (Est.)
EPS Estimate
1.53
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Recurring Consumables Model

Illumina’s instrument base creates recurring demand for sequencing consumables as customers run more experiments and tests. Continued NovaSeq X placements and rising utilization can expand this installed-base annuity, supporting revenue visibility and reinforcing the company’s workflow position over the next several quarters.

Clinical Sequencing Growth

Strong clinical consumables growth indicates that sequencing adoption is advancing in applications with ongoing testing and trial activity. Management’s continued mid-teens clinical growth outlook, supported by a pipeline of tests, provides a durable counterweight to weaker research demand.

Improved Profitability And Cash Generation

The recent return to profitability alongside substantial free cash flow strengthens Illumina’s ability to fund product development, support customers, and manage obligations internally. High gross margin and strong earnings conversion also provide operating capacity if market conditions remain uneven.

Bears Say

Research Market Weakness

Research and applied markets remain a meaningful source of pressure, with management still expecting mid- to high-single-digit consumables declines in 2026. Prolonged weakness can reduce instrument utilization and consumables pull-through, slowing growth while clinical demand expands.

Pricing And Cost Pressure

Persistent input, logistics, tariff, and transition-related pricing pressures can limit margin durability even as operating performance improves. These factors may require continued execution and productivity gains to preserve profitability while the NovaSeq X platform scales.

Earnings Volatility

The sharp multi-year swings in profitability make current earnings less predictable than the latest results alone suggest. Uneven revenue trends and prior losses could constrain confidence in sustainable margins, particularly if research weakness or other operating headwinds persist.

Illumina News

ILMN FAQ

What was Illumina’s price range in the past 12 months?
Illumina lowest stock price was $112.65 and its highest was $309.35 in the past 12 months.
What is Illumina’s market cap?
Illumina’s market cap is $32.20B.
When is Illumina’s upcoming earnings report date?
Illumina’s next earnings report is estimated for Feb 11, 2027 (not yet confirmed), which is in 90 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on Oct 29, 2026. The company reported $1.44 earnings per share for the quarter, beating the consensus estimate of $1.356 by $0.084.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Undervalued.
Does Illumina pay dividends?
Illumina does not currently pay dividends.
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 1.53.
How many shares outstanding does Illumina have?
Illumina has 151,200,000 shares outstanding.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of $1.44 in its last earnings report, beating expectations of $1.356. Following the earnings report the stock price went down -18.641%.
Which hedge fund is a major shareholder of Illumina?
Hedge funds hold Illumina shares: the largest hedge-fund position in Illumina is 71,885,245 shares, and hedge funds decreased their holdings by 76.3K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology